Binqing Fu
University of Science and Technology of China · 118 works · 8,717 citations · h-index 33
Top works
- Effective treatment of severe COVID-19 patients with tocilizumab
- Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
- Why tocilizumab could be an effective treatment for severe COVID-19?
- Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm
- Natural Killer Cells Promote Fetal Development through the Secretion of Growth-Promoting Factors
- Natural killer cells promote immune tolerance by regulating inflammatory T H 17 cells at the human maternal–fetal interface
- Dysfunction of Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer Progression
- Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance
- TGF-β1 Down-Regulation of NKG2D/DAP10 and 2B4/SAP Expression on Human NK Cells Contributes to HBV Persistence
- CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells
- Subsets of human natural killer cells and their regulatory effects
- TH17 cells in human recurrent pregnancy loss and pre-eclampsia
- IGF-1 promotes the development and cytotoxic activity of human NK cells
- Tumors evade immune cytotoxicity by altering the surface topology of NK cells
- Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation
- Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
- Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling
- LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia
- Involvement of CD226+ NK Cells in Immunopathogenesis of Systemic Lupus Erythematosus
- Tocilizumab Ameliorates the Hypoxia in COVID-19 Moderate Patients with Bilateral Pulmonary Lesions: A Randomized, Controlled, Open-Label, Multicenter Trial